Impact of alirocumab on Lp(a) in individuals with and without moderate CKD

Back

ESC Premium Access

Impact of alirocumab on Lp(a) in individuals with and without moderate CKD

Session: Lipids and platelets

Topic: Lipids

Speaker: Professor P. Toth (Baltimore, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Peter Toth

CGH Medical Center and The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore (United States of America)

5 presentations

0 follower

6 more presentations in this session

Inhibition of lipopolysaccharide induced gene expression by HDL from healthy subjects and patients with acute myocardial infarction

Speaker: Assistant Professor S. Imaizumi (Fukuoka, JP)

Access

Abstract

Association of the postprandial chylomicron triglyceride/apoB index and cardiovascular events

Speaker: Doctor C. Werner (Homburg, DE)

Access

Abstract

Slides

Malondialdehyde assay in evaluation of aspirin antiplatelet effects

Speaker: Mrs L. Dannenberg (Duesseldorf, DE)

Access

Abstract

Slides

C2238 atrial natriuretic peptide molecular variant determines an increased platelet aggregation through the activation of NOX2 and the reduction of cAMP

Speaker: Assistant Professor S. Sciarretta (Rome, IT)

Access

Abstract

Efficacy and safety of alirocumab in patients with multiple manifestations of cardiovascular disease (CVD): a post-hoc analysis of ODYSSEY program

Speaker: Professor K. Ray (London, GB)

Access

Abstract

Slides

Access the full session

Lipids and platelets

Speakers: Professor P. Toth, Assistant Professor S. Imaizumi, Doctor C. Werner, Mrs L. Dannenberg, Assistant Professor S. Sciarretta...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources